Thus, given that ACE2 is expressed at much lower levels in the lungs than the heart and since one study involving 58 patients found that ACE inhibitors/angiotensin II receptor blockers have no significant effect on the outcome and prognosis of COVID-19 patients with hypertension [55], this raises questions about the evidence for the correlation between ACE2 levels and infectivity of SARS-CoV-2. The gene discussed is ACE2; the disease is hypertensive disorder.